Investigators present findings from a double-blind randomized controlled trial of personalized stimulation of the left dorsolateral prefrontal cortex using transcranial magnetic stimulation to increase hypnotizability in a sample of patients with fibromyalgia syndrome.
A researcher explains the new ketamine trials in patients with depression, and why they show more promise than traditional anti-depressants.
A recent study in mice reveals that targeting ENPP1 could enhance immunotherapy effectiveness, offering hope for better breast cancer treatment outcomes. In Forbes:
What changes in cells lead to breast cancer? Scientists now have access to the world’s most comprehensive atlas of healthy breast tissue to help answer this question. 7 years in the making, the Human Breast Cell Atlas is helping scientists better understand breast cancer and other diseases to find new treatments.
In three patients with Alzheimer’s disease, focused ultrasound was applied with aducanumab therapy. Reduction in amyloid was greater in treated regions than in matched contralateral regions over 6 months. Read the full report:
Original Article from The New England Journal of Medicine — Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease.
Hmmm I wonder if this can lead to allergies and inflammation. I googled it. Yes it can lead to allergies. Maybe that’s why I can’t drink coffee anymore or Earl Grey Tea. Another Google search says it can lead to inflammation which causes a lot of health problems.
You may think that artificial sweeteners can help you lose some weight, but a new study finds they are no good for your gut’s microbiome.
People who use aspartame (Equal), sucralose (Splenda), saccharin (Sweet’N Low), or stevia leaf extract tended to have intestinal bacteria colonies that differed significantly from those of people who didn’t use sugar substitutes, researchers found.
Continue reading “Could artificial sweeteners alter your microbiome?” »
Eli Lilly & Novartis are entering a strategic research collaboration with Isomorphic Labs to use state-of-the-art AI technologies—including the next-gen model of #AlphaFold—to discover novel small molecule therapeutics for select biological targets.
We are reimagining the entire drug discovery process from first principles with an AI-first approach.
Dementia and stroke often have devastating consequences, so patients want to know what they can do to protect themselves against these diseases. A team of clinicians in partnership with patients developed a Brain Care Score (BCS) based on modifiable risk factors identified in past epidemiological studies. In the BCS, weights are assigned to four physical components (i.e., blood pressure, glycosylated hemoglobin, cholesterol, and body-mass index), to five lifestyle elements (i.e., nutrition, alcohol intake, smoking, aerobic activities, and sleep), and to three social factors (i.e., stress, relationships, and purpose in life). Lower scores on the BCS (range, 0–19) predict higher risk.
The team then validated whether the BCS predicted new dementia or stroke in the U.K. Biobank cohort, which consisted of 398,900 people (age range at baseline, 40–69). During average follow-up of nearly 13 years, new dementia or stroke occurred in ≈3% of the cohort. The BCS identified people who were at highest risk for these outcomes. For example, among those who were younger than 50 at baseline, a 5-point higher score predicted 59% lower risk for dementia and 48% lower risk for stroke.
This score could be computed automatically from information already in electronic health records and used to identify risk factors and to engage patients in modifying those risk factors. Whether such scoring would actually lead to lower incidences of dementia and stroke remains to be seen.
Edwin Ostrin, M.D., Ph.D., discusses the ongoing research into whether vaping is linked to lung cancer and other lung health issues.
The technique of inhaling nanoparticle sensors followed by a urine test may offer the potential for faster and early detection of lung cancer.
Scientists from the Massachusetts Institute of Technology (MIT) have introduced this cutting-edge medical technology, presenting a simplified approach to diagnosing lung cancer.
Additionally, this innovation holds particular promise for low-and middle-income countries where the accessibility of computed tomography (CT) scanners is limited.
